NCT lookup

Inclusion Criteria:

* Type 1 Diabetes for at least 1 year on continuous subcutaneous insulin infusion (CSII; also known as insulin pump)
* HbA1c of 7-10% (inclusive)
* Ages 18-65 years (inclusive of ages 18 and 65)
* BMI 20-30 kg/m2

Exclusion Criteria:

* Inability to give informed consent
* Inability or refusal to comply with protocol
* Use of GLP-1 Receptor Agonists in the last 3 months or DPP-IV and SGLT-2 inhibitors therapy in the last 1 month.
* Risk for pancreatitis (e.g., history of gallstones, alcohol abuse, and hypertriglyceridemia)
* History of pancreatitis and or chronic pancreatitis
* Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) or stroke in the previous 3 months.
* Congestive Heart Failure class III or IV or tachyarrhythmia.
* Hepatic disease: Severe hepatic insufficiency and/or significant abnormal liver function defined as:

  1. Aspartate aminotransferase (AST) \>3x upper limit of normal (ULN) and/or alanine aminotransferase (ALT) \>3x ULN
  2. Total bilirubin \>2.0 mg/dL (34.2 µmol/L)
  3. Positive serologic evidence of current infectious liver disease including Hepatitis B viral antibody IGM, Hepatitis B surface antigen and Hepatitis C virus antibody
  4. Liver function tests more than 3 times the upper limit of normal
* Renal impairment (e.g., serum creatinine levels ≥1.4 mg/dL for women, or eGFR \<60 mL/min/1.73 m2) or history of unstable or rapidly progressing renal disease or end stage renal disease.
* History of unexplained microscopic or gross hematuria, or microscopic hematuria at visit 1, confirmed by a follow-up sample at next scheduled visit.
* HIV positive
* History of gastroparesis
* History of medullary thyroid carcinoma or MEN 2 syndrome
* History of recurring UTI
* Uncontrolled thyroid disease (documented normal TSH), Cushing's syndrome, congenital adrenal hyperplasia or hyperprolactinemia.
* Prior history of a malignant disease requiring chemotherapy or patients with a prior history of bladder cancer regardless of treatment
* Alcoholism or drug addiction.
* Hypertriglyceridemia (\>400 mg/dl).
* Any other life-threatening, non-cardiac disease
* Uncontrolled hypertension (BP \> 160/95 mm of Hg)
* Patients with hypotension or at risk for volume depletion due to co-existing conditions or concomitant medications, such as loop diuretics or recently donated \>500ml of blood should have careful monitoring of their volume status
* Pregnant or breastfeeding patients or patient not willing to use two barrier method contraception during study period (unless sterilized or have an IUD)
* Use of hormonal medications, anti-obesity drugs or weight loss medications (prescription or OTC) and medications known to exacerbate glucose tolerance (such as isotretinoin, GnRH agonists, glucocorticoids, anabolic steroids, C-19 progestins) stopped for at least 8 weeks. Use of anti-androgens that act peripherally to reduce hirsutism such as 5-alpha reductase inhibitors (finesteride, spironolactone, flutamide) stopped for at least 4 weeks
* Presence of hypersensitivity to dapagliflozin or other SGLT2 inhibitors (e.g. anaphylaxis, angioedema, exfoliative skin conditions
* Known hypersensitivity or contraindications to use GLP1 receptor agonists (exenatide, liraglutide)
* Known hypersensitivity to heparin/ IV catheter equipment.
* Eating disorders (anorexia, bulimia) or gastrointestinal disorders
* Having a history of bariatric surgery
* Debilitating psychiatric disorder such as psychosis or neurological condition that might confound outcome variables
* Use of an investigational agent or therapeutic regimen within 30 days of study
* Participation in any other concurrent clinical trial

• Williamsville, New York, United States